Drug Profile
Stavudine
Alternative Names: BMY 27857; d4T; Zerit; ZeritavirLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Yale University; Yamasa Corporation
- Developer Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation; Yamasa Corporation
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 18 Feb 2011 EMA CHMP recommends limited use of stavudine in Europe
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 19 Aug 2003 The CPMP has recommended approval of stavudine for use in paediatric patients less than 3 months old in the EU